Clinical trials: Heart Infarction
Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation, ECLS, VA ECMO
- Trial name
- PulseSE (NCT05106491)
- Testing
- Synchronized Cardiac Support with the icor kit
- Where
- 2 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Xenios AG
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Coronary Artery Disease, Myocardial Infarction
Disrupt CAD III Post-Approval Study (PAS)
The study design is a prospective, multicenter, observational, single-arm post-approval study using data collected in the National Cardiovascular Data Registry (NCDR®) CathPCI Registry®.
- Trial name
- NCT05021757
- Testing
- Shockwave C2 Coronary IVL
- Where
- United States
- Volunteers
- 1,212 people
- Sponsor
- Shockwave Medical, Inc.
Acute ST Elevation Myocardial Infarction
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI
This study is aiming to test the hypothesis that efficacy of rhTNK-tPA was not inferior to rt-PA with respect to the 30-day MACCE rates after fibrinolytic therapy for STEMI patients.
- Trial name
- NCT02835534
- Testing
- rhTNK-tPA, alteplase
- Where
- China
- Volunteers
- 818 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Unstable Angina, Myocardial Infarction
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
Patients experiencing a mild heart attack will receive one of two medications which thin the blood to discern which is superior.
- Conditions
- Unstable Angina, Myocardial Infarction, Myocardial Ischemia
- Trial name
- NCT00043784
- Testing
- enoxaparin
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Sanofi
Coronary Stenosis, Acute Coronary Syndrome
Coronary Plaque Geometry and Acute Coronary Syndromes
The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography…
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atherosclerosis
- Trial name
- NCT03702764
- Testing
- CCTA
- Where
- Romania
- Volunteers
- 1,000 people
- Sponsor
- Cardio Med Medical Center
Myocardial Infarction
Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI
The purpose of this study is to demonstrate the benefit of bivalirudin in combination with clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications associated with early invasive management of…
- Trial name
- NCT00093184
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- The Medicines Company
Acute Myocardial Infarction
MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction
The MAGNetic QRS-Fragmentation in Patients with Myocardial InfarcTion and Moderately RedUceD Ejection Fraction (MAGNITUDE) study will assess in MI survivors with moderately reduced left ventricular function, whether non-invasive…
- Trial name
- MAGNITUDE (NCT01972126)
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Myocardial Infarction
Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients.
The primary objective of the study is to determine the feasibility and safety of intracoronary administration of autologous bone marrow derived mononuclear cell product in patients at risk for clinically significant cardiac…
- Trial name
- AMIRST (NCT01536106)
- Testing
- Autologous Bone marrow mononuclear cells
- Where
- 3 sites in India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- TotipotentRX Cell Therapy Pvt. Ltd.
Cardiogenic Shock
Abiomed Impella RT-DAQ - Observational Study
Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition
- Trial name
- NCT06308055
- Testing
- Data Acquisition
- Where
- 4 sites in Germany, Italy and 1 more
- Volunteers
- 125 people
- Sponsor
- Abiomed Inc.
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Heart Diseases, ASD - Atrial Septal Defect
Abbott Structural Heart Device Registry
The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting.
- Conditions
- Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
- Trial name
- SH-Registry (NCT06590467)
- Testing
- Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
- Where
- 36 sites in United States, Denmark and 8 more
- Volunteers
- 2,500 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Diseases
BIOTRONIK - BIOFLOW-III Registry French Satellite
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success.
- Trial name
- NCT02273648
- Testing
- Drug Eluting Stent (DES)
- Where
- 50 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Biotronik France
ST-elevation MI, Hypothermia
Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients
This study will look at the safety of treating patients with heart attack with mild hypothermia induced using a system of automated peritoneal lavage.
- Trial name
- VELOCITY (NCT01655433)
- Testing
- Velomedix APLS device, No Hypothermia Treatment
- Where
- 7 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Velomedix, Inc.
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in STROke Recovery
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAEStro (NCT05046106)
- Testing
- MLC1501
- Volunteers
- 540 people
- Sponsor
- Moleac Pte Ltd.
Coronary Artery Disease, Myocardial Ischemia
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
The purpose of this study is to evaluate the safety and feasibility of a new coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- MEND II (NCT02189499)
- Testing
- AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 4 sites in Colombia
- Volunteers
- 42 people
- Sponsor
- Amaranth Medical Inc.
Myocardial Infarction
A Study of NP-011 in Healthy Volunteers
This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.
- Trial name
- NCT05387499
- Testing
- NP-011 (Single Ascending Dose Phase), NP-011 (Multiple Ascending Dose Phase)
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Nexel Co., Ltd.